Source-grounded facts extracted from PSYCHEMEDICS CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PSYCHEMEDICS CORP reported the first quarter ended March 31, 2024 results: revenue $5.4 million, net income $0.7 million, EPS $0.12 per share.
“The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $.07 per share, for the comparable quarter last year.”
PSYCHEMEDICS CORP reported the year ended December 31, 2023 results: revenue $22.1 million, net income net loss of approximately $4.2 million, EPS $0.72 per share.
“but also solidify our position as the leader in the industry,” added Shannon Shoemaker, Chief Revenue Officer. The Company's revenue for the year ended December 31, 2023, was $22.1 million versus $25.2 million for the prior year, a decrease of 12%. As of December 31, 2023, the Company had cash and cash equivalents of approximately $2.0 million, compared with”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.